UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options and sold 9,500 shares of UTHR common stock via a 10b5‑1 trading plan through a family trust.

On August 12, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, through an indirectly owned family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equal number of common shares, then sold 9,500 shares of United Therapeutics common stock in a series of open‑market transactions at prices mostly between roughly $507 and $521 per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan. The gross value of the option exercise (measured at the reported fair value of $151.41 per share) was about $1.44 million, while the aggregate sale proceeds were approximately $4.9 million, leaving the reporting person and related family trusts and spouse with an aggregate indirect and direct ownership position of roughly 333,943 shares in the primary trust plus additional direct and trust holdings. The filing notes that the 10b5‑1 plan, adopted on November 7, 2025, is intended to facilitate the orderly exercise of up to 1,734,410 options expiring March 15, 2027, or until December 31, 2026, and clarifies that all shares involved are held through various family trust structures in which the reporting person and/or her spouse and immediate family members have beneficial interests.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000119

Alert Tier

6